Mounjaro is a medication that is approved to improve blood sugar control in adults with type 2 diabetes. Recently, Mounjaro received approval for weight loss in adults with obesity (BMI≥30) or overweight (BMI≥27) with a weight-related condition. Both Mounjaro and Zepbound (available in the US) have the same active ingredient, tirzepatide.

Tirzepatide, including both Mounjaro (FDA-approved for treatment of type 2 diabetes) and Zepbound (FDA-approved for weight loss), is a glucagon-like peptide 1 (GLP-1) receptor agonist and a glucose-dependent insulinotropic polypeptide (GIP) agonist. This means that tirzepatide acts like the GLP-1 and GIP hormones to lower blood sugar levels and decrease your appetite so you lose weight. It also slows down how fast food moves through your body, which may help you stay full for longer. Both Mounjaro and Zepbound are once-weekly medications administered via a single-use prefilled injection pen with the prescribed dose. You administer the injection under the skin of your stomach, thigh, or arm.

Research shows, on average, an individual can expect to lose 20% total body weight loss in a little over a year of taking Mounjaro in combination with a healthy lifestyle.

Please click the button 'SPEAK TO A PHARMACIST' for our on-site team of pharmacists to talk you through a consultation asking your previous medical history, any other prescriptions and BMI information.